ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Strebel P , Orenstein W , 2019. Measles. N Engl J Med 381: 349–357.
-
2.
Guerra FM , Crowcroft NS , Friedman L , Deeks SL , Halperin SA , Severini A , Hatchette TF , Bolotin S , 2018. Waning of measles maternal antibody in infants in measles elimination settings – a systematic literature review. Vaccine 36: 1248–1255.
-
3.
Murray AF , Englund JA , Tielsch JM , Katz J , Shrestha L , Khatry SK , Carlin K , Leclerq SC , Steinhoff MC , Chu HY , 2018. Measles and rubella seroprevalence in mother-infant pairs in rural Nepal and the United States: pre- and post-elimination populations. Am J Trop Med Hyg 99: 1342–1345.
-
4.
Thompson KM , Odahowski CL , 2016. Systematic review of measles and rubella serology studies. Risk Anal Off Publ Soc Risk Anal 36: 1459–1486.
-
5.
Strebel PM , Papania MJ , Gastanaduy PA , Goodson JL , Orenstein WA , Offit PA , Edwards KM & Plotkin SA Plotkin’s Vaccines. 7th ed. Philadelphia, PA: Elsevier, 579–618.
-
6.
José Manuel Borgoño Z , 1983. Current impact of measles in Latin America. Rev Infect Dis 5: 417–421.
-
7.
Castillo-Solorzano CC , Matus CR , Flannery B , Marsigli C , Tambini G , Andrus JK , 2011. The Americas: paving the road toward global measles eradication. J Infect Dis 204: S270–S278.
-
8.
PAHO , 1962. Health Conditions in the Americas, 1957–1960. Washington, DC: Panamerican Health Organization.
-
9.
PAHO , 1986. Health Conditions in the Americas, 1981–1984 v1. Washington, DC: Panamerican Health Organization.
-
10.
Kraus N , Condon SB , 2021. Measles (Rubeola): a case of vaccine hesitancy and pregnancy. J Midwifery Womens Health 66: 391–396.
-
11.
McNally VV , Bernstein HH , 2020. The effect of the COVID-19 pandemic on childhood immunizations: ways to strengthen routine vaccination. Pediatr Ann 49: e516–e522.
-
12.
Patel MK et al., 2020. Progress toward regional measles elimination—worldwide, 2000–2019. MMWR Morb Mortal Wkly Rep 69: 1700.
-
13.
Hotez PJ , Nuzhath T , Colwell B , 2020. Combating vaccine hesitancy and other 21st century social determinants in the global fight against measles. Curr Opin Virol 41: 1–7.
-
14.
World Health Organization , 2020. Immunization, vaccines and biologicals. vaccine preventable diseases vaccines monitoring system 2020 global summary reference time series: MEASLES. Available at: https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencemeasles.html. Accessed May 21, 2021.
-
15.
Feemster KA , Szipszky C , 2020. Resurgence of measles in the United States: how did we get here? Curr Opin Pediatr 32: 139–144.
-
16.
Hayman DT , 2019. Measles vaccination in an increasingly immunized and developed world. Hum Vaccin Immunother 15: 28–33.
-
17.
World Health Organization , 2019. Measles vaccines: WHO position paper, April 2017—Recommendations. Vaccine 37: 219–222.
-
18.
Winter AK , Martinez ME , Cutts FT , Moss WJ , Ferrari MJ , McKee A , Lessler J , Hayford K , Wallinga J , Metcalf CJE , 2018. Benefits and challenges in using seroprevalence data to inform models for measles and rubella elimination. J Infect Dis 218: 355–364.
-
19.
Hincapié-Palacio D et al., 2019. Serosurveillance for vaccine-preventable diseases: a look inside the pertussis experience. Biomed Rev Inst Nac Salud 39: 130–143.
-
20.
Durrheim D , 2018. Measles elimination, immunity, serosurveys, and other immunity gap diagnostic tools. J Infect Dis 218: 341–343.
-
21.
Gonçalves G , Nunes C , Mesquita J , Nascimento MSJ , Frade J , 2016. Measles antibodies in cord blood in Portugal: possible consequences for the recommended age of vaccination. Vaccine 34: 2750–2757.
-
22.
Congera P , Maraolo AE , Parente S , Schiano Moriello N , Bianco V , Tosone G , 2020. Measles in pregnant women: a systematic review of clinical outcomes and a meta-analysis of antibodies seroprevalence. J Infect 80: 152–160.
-
23.
Leuridan E , Nunes M , Jones C , 2019. Maternal Immunization. San Diego, CA: Academic Press.
-
24.
Hincapié-Palacio D , Hoyos MC , Ochoa J , Montoya N , García D , Osorio E , 2018. Effect of maternal immunization against pertussis in Medellin and the metropolitan area, Colombia, 2016–2017. Vaccine 36: 3984–3991.
-
26.
Mayor Mora A , Menjura F , Arias A , 2010. Cruzada interminable por la niñez colombiana: historia del Programa Ampliado de Inmunizaciones (PAI) en Colombia 1979–2009. Bogotá Minist Protección Soc Organ Panam Salud 2: 1979–2009.
-
27.
Morón-Duarte LS , Castillo-Pabón JO , 2012. La vigilancia epidemiológica de sarampión y rubéola en el marco del plan de eliminación: Colombia 1995–2009. Rev Salud Publica (Bogota) 14: 1–14.
-
28.
Hincapie-Palacio D , Lenis Ballesteros V , Ospina MC , Toro OLP , Díaz FJ , 2013. Seroprevalence of rubella in Colombia: a birth-year cohort analysis. Rev Saude Publica 47: 1080–1091.
-
29.
Velandia M , Castillo O , Higuera AB , Pastor D , 2004. Eliminación de la rubéola y el síndrome de rubéola congénita, plan de acción 2004–2010. Inf Quinc Epidemiol Nac 9: 321–336.
-
30.
Pinto DM , Muñoz AL , 2010. Colombia: Sistema general de seguridad social en salud. Estrategia del BID 2011–2014. Washington, DC: División de Protección Social y Salud, Inter-American Development Bank.
-
31.
De los Angeles Rodríguez M , Restrepo C , Uribe G , Díaz FJ , Jaramillo N , Melguizo M , 1999. Estado serológico para sarampión en población de uno a 14 años. Medellín 1996. Colomb Med (Cali) 30: 8–82.
-
32.
Bermúdez-Forero A , Mercado-Reyes M , Tavera P , Rey-Benito G , 2007. Determinación de la potencia del componente “sarampión” de la vacuna de virus vivo de sarampión y rubéola USP utilizada en la jornada de vacunacion 2005. Univ Sci (Bogota) 12: 87–94.
-
33.
Mercado MM , Rey G , Gutiérrez MF , Ruíz JG , Trespalacios AA , Bermudez A del P , 2009. Estimación de la proporción de seropositividad contra el sarampión en madres y presencia de anticuerpos antes y después de la vacuna en sus hijos de 6 y 12 meses de edad. Pediatria (Napoli) 42: 25–37.
-
34.
National Institute of Health, Republic of Colombia , 2019. PortalSivigila 2019 Buscador. Available at: http://portalsivigila.ins.gov.co/Paginas/Buscador.aspx#. Accessed November 25, 2020.
-
35.
Plotkin SA , 2020. Is there a correlate of protection for measles vaccine? J Infect Dis 221: 1571–1572.
-
36.
Bolotin S et al., 2020. What Is the evidence to support a correlate of protection for measles? A systematic review. J Infect Dis 221: 1576–1583.
-
37.
Ministerio de Salud y Protección Social, Republic of Colombia Información vacunas y programas de vacunación Ministerio de Salud Colombia. Available at: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/pai.aspx. Accessed July 10, 2021.
-
38.
Cetin Coban S et al., 2019. Prevalence of protective measles virus antibody levels in umbilical cord blood samples and sera of mothers and transplacental transport ratio in Turkey. Jpn J Infect Dis 72: 185–192.
-
39.
Gieles NC , Mutsaerts E , Kwatra G , Bont L , Cutland CL , Jones S , Moultrie A , Madhi SA , Nunes MC , 2020. Measles seroprevalence in pregnant women in Soweto, South Africa: a nested cohort study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 26: 515.e1–515.e4.
-
40.
Lam MTC , Schmidt-Beuchat E , Geduldig E , Brustman LE , Choi KH , Overbey JR , Woods KL , Al-Ibraheemi Z , 2021. What is the prevalence of measles immunity among pregnant women? Am J Perinatol 38: 16–22.
-
41.
Lee Y-C , Lee Y-H , Lu C-W , Cheng S-Y , Yang K-C , Huang K-C , 2020. Measles immunity gaps in an era of high vaccination coverage: a serology study from Taiwan. Travel Med Infect Dis 36: 101804.
-
42.
Gonçalves G , Frade J , Nunes C , Mesquita JR , Nascimento MSJ , 2015. Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal. Vaccine 33: 5057–5063.
-
43.
Poethko-Müller C , Mankertz A , 2012. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One 7: e42867.
-
44.
Vandermeulen C , Mathieu R , Geert L-R , Pierre VD , Karel H , 2007. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 25: 6672–6676.
-
45.
Arora M , Lakshmi R , 2021. Maternal vaccines—safety in pregnancy. Best Pract Res Clin Obstet Gynaecol 76: 23–40.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1856 | 1217 | 56 |
| Full Text Views | 233 | 35 | 0 |
| PDF Downloads | 120 | 30 | 0 |
Measles Serostatus in Mothers and Their Newborns in Antioquia, Colombia: Implications for Measles Elimination
Eduardo Santacruz-Sanmartin
Eduardo Santacruz-Sanmartin
“Héctor Abad Gómez” National Faculty of Public Health, Universidad of Antioquia, Medellin, Colombia;
Search for other papers by Eduardo Santacruz-Sanmartin in
Current site
Google Scholar
PubMed
Search for other papers by Eduardo Santacruz-Sanmartin in
Current site
Google Scholar
PubMed
Doracelly Hincapié-Palacio
Doracelly Hincapié-Palacio
“Héctor Abad Gómez” National Faculty of Public Health, Universidad of Antioquia, Medellin, Colombia;
Search for other papers by Doracelly Hincapié-Palacio in
Current site
Google Scholar
PubMed
Search for other papers by Doracelly Hincapié-Palacio in
Current site
Google Scholar
PubMed
Jesús E. Ochoa-Acosta
Jesús E. Ochoa-Acosta
“Héctor Abad Gómez” National Faculty of Public Health, Universidad of Antioquia, Medellin, Colombia;
Search for other papers by Jesús E. Ochoa-Acosta in
Current site
Google Scholar
PubMed
Search for other papers by Jesús E. Ochoa-Acosta in
Current site
Google Scholar
PubMed
Seti Buitrago-Giraldo
Seti Buitrago-Giraldo
Departmental Laboratory of Public Health, The Sectional Secretariat of Health and Social Protection of Antioquia, Medellin, Colombia
Search for other papers by Seti Buitrago-Giraldo in
Current site
Google Scholar
PubMed
Search for other papers by Seti Buitrago-Giraldo in
Current site
Google Scholar
PubMed
Marta C. Ospina
Marta C. Ospina
Departmental Laboratory of Public Health, The Sectional Secretariat of Health and Social Protection of Antioquia, Medellin, Colombia
Search for other papers by Marta C. Ospina in
Current site
Google Scholar
PubMed
Search for other papers by Marta C. Ospina in
Current site
Google Scholar
PubMed
ABSTRACT.
To describe the serostatus of measles IgG antibodies in pregnant women and newborns, placental transfer, and factors that determine being below the threshold of 150 mIU/mL, a cross-sectional study was conducted. Blood samples of 790 pregnant women at the time of delivery and 734 umbilical cord samples were analyzed from eight hospitals in the Aburrá Valley of Antioquia, Colombia. Measles IgG antibody measurement was performed with ELISA. The proportion of individuals with antibodies < 150 mIU/mL was 13.9% (95% CI: 12.2–15.8) in pregnant women and 11.1% (95% CI: 9.2–13.4) in newborns. The geometric mean of the antibody level of the pregnant women was 552 mIU/mL (95% CI: 504–605) and in the umbilical cord 662 mIU/mL (95% CI: 604–727). A positive correlation between pregnant woman and umbilical cord antibodies was found. The median ratio of measles IgG antibodies in umbilical cord/pregnant woman was 1.22 for all participants. A seroprevalence below the threshold of 150 mIU/mL was found in newborns whose mothers were born between 1983 and 1994, compared with those born before that period, when exposure to the wildtype virus was common (adjusted prevalence ratio: 3.6, 95% CI: 1.3–9.6). These findings suggest that there are gaps in measles immunity among women of childbearing age, before pregnancy. To close this immune gap and support efforts to maintain measles control, serological screening for measles antibodies should be routinely included in reproductive health and antenatal care programs to identify women without immunity who should be vaccinated before pregnancy or after delivery.
Author Notes
Financial support: This work was financed by the Administrative Department of Science, Technology and Innovation “COLCIENCIAS—Minciencias” Colombia (grant no. 699-2018), Departmental Laboratory of Public Health of the Sectional Secretariat of Health and Social Protection of Antioquia, Secretary of Health of Medellin and The University of Antioquia, Medellin, Colombia.
Authors’ addresses: Eduardo Santacruz-Sanmartin, Doracelly Hincapié-Palacio, and Jesús E. Ochoa-Acosta, “Héctor Abad Gómez” National Faculty of Public Health, Universidad of Antioquia, Medellín, Colombia, E-mails: eduardo.santacruz@udea.edu.co, doracelly.hincapie@udea.edu.co, and jesus.ochoa@udea.edu.co. Seti Buitrago-Giraldo and Marta C. Ospina, Departmental Laboratory of Public Health, The Sectional Secretariat of Health and Social Protection of Antioquia, Medellín, Colombia, E-mails: seti.buitrago@antioquia.gov.co and martha.ospina@antioquia.gov.co.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Strebel P , Orenstein W , 2019. Measles. N Engl J Med 381: 349–357.
-
2.
Guerra FM , Crowcroft NS , Friedman L , Deeks SL , Halperin SA , Severini A , Hatchette TF , Bolotin S , 2018. Waning of measles maternal antibody in infants in measles elimination settings – a systematic literature review. Vaccine 36: 1248–1255.
-
3.
Murray AF , Englund JA , Tielsch JM , Katz J , Shrestha L , Khatry SK , Carlin K , Leclerq SC , Steinhoff MC , Chu HY , 2018. Measles and rubella seroprevalence in mother-infant pairs in rural Nepal and the United States: pre- and post-elimination populations. Am J Trop Med Hyg 99: 1342–1345.
-
4.
Thompson KM , Odahowski CL , 2016. Systematic review of measles and rubella serology studies. Risk Anal Off Publ Soc Risk Anal 36: 1459–1486.
-
5.
Strebel PM , Papania MJ , Gastanaduy PA , Goodson JL , Orenstein WA , Offit PA , Edwards KM & Plotkin SA Plotkin’s Vaccines. 7th ed. Philadelphia, PA: Elsevier, 579–618.
-
6.
José Manuel Borgoño Z , 1983. Current impact of measles in Latin America. Rev Infect Dis 5: 417–421.
-
7.
Castillo-Solorzano CC , Matus CR , Flannery B , Marsigli C , Tambini G , Andrus JK , 2011. The Americas: paving the road toward global measles eradication. J Infect Dis 204: S270–S278.
-
8.
PAHO , 1962. Health Conditions in the Americas, 1957–1960. Washington, DC: Panamerican Health Organization.
-
9.
PAHO , 1986. Health Conditions in the Americas, 1981–1984 v1. Washington, DC: Panamerican Health Organization.
-
10.
Kraus N , Condon SB , 2021. Measles (Rubeola): a case of vaccine hesitancy and pregnancy. J Midwifery Womens Health 66: 391–396.
-
11.
McNally VV , Bernstein HH , 2020. The effect of the COVID-19 pandemic on childhood immunizations: ways to strengthen routine vaccination. Pediatr Ann 49: e516–e522.
-
12.
Patel MK et al., 2020. Progress toward regional measles elimination—worldwide, 2000–2019. MMWR Morb Mortal Wkly Rep 69: 1700.
-
13.
Hotez PJ , Nuzhath T , Colwell B , 2020. Combating vaccine hesitancy and other 21st century social determinants in the global fight against measles. Curr Opin Virol 41: 1–7.
-
14.
World Health Organization , 2020. Immunization, vaccines and biologicals. vaccine preventable diseases vaccines monitoring system 2020 global summary reference time series: MEASLES. Available at: https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencemeasles.html. Accessed May 21, 2021.
-
15.
Feemster KA , Szipszky C , 2020. Resurgence of measles in the United States: how did we get here? Curr Opin Pediatr 32: 139–144.
-
16.
Hayman DT , 2019. Measles vaccination in an increasingly immunized and developed world. Hum Vaccin Immunother 15: 28–33.
-
17.
World Health Organization , 2019. Measles vaccines: WHO position paper, April 2017—Recommendations. Vaccine 37: 219–222.
-
18.
Winter AK , Martinez ME , Cutts FT , Moss WJ , Ferrari MJ , McKee A , Lessler J , Hayford K , Wallinga J , Metcalf CJE , 2018. Benefits and challenges in using seroprevalence data to inform models for measles and rubella elimination. J Infect Dis 218: 355–364.
-
19.
Hincapié-Palacio D et al., 2019. Serosurveillance for vaccine-preventable diseases: a look inside the pertussis experience. Biomed Rev Inst Nac Salud 39: 130–143.
-
20.
Durrheim D , 2018. Measles elimination, immunity, serosurveys, and other immunity gap diagnostic tools. J Infect Dis 218: 341–343.
-
21.
Gonçalves G , Nunes C , Mesquita J , Nascimento MSJ , Frade J , 2016. Measles antibodies in cord blood in Portugal: possible consequences for the recommended age of vaccination. Vaccine 34: 2750–2757.
-
22.
Congera P , Maraolo AE , Parente S , Schiano Moriello N , Bianco V , Tosone G , 2020. Measles in pregnant women: a systematic review of clinical outcomes and a meta-analysis of antibodies seroprevalence. J Infect 80: 152–160.
-
23.
Leuridan E , Nunes M , Jones C , 2019. Maternal Immunization. San Diego, CA: Academic Press.
-
24.
Hincapié-Palacio D , Hoyos MC , Ochoa J , Montoya N , García D , Osorio E , 2018. Effect of maternal immunization against pertussis in Medellin and the metropolitan area, Colombia, 2016–2017. Vaccine 36: 3984–3991.
-
26.
Mayor Mora A , Menjura F , Arias A , 2010. Cruzada interminable por la niñez colombiana: historia del Programa Ampliado de Inmunizaciones (PAI) en Colombia 1979–2009. Bogotá Minist Protección Soc Organ Panam Salud 2: 1979–2009.
-
27.
Morón-Duarte LS , Castillo-Pabón JO , 2012. La vigilancia epidemiológica de sarampión y rubéola en el marco del plan de eliminación: Colombia 1995–2009. Rev Salud Publica (Bogota) 14: 1–14.
-
28.
Hincapie-Palacio D , Lenis Ballesteros V , Ospina MC , Toro OLP , Díaz FJ , 2013. Seroprevalence of rubella in Colombia: a birth-year cohort analysis. Rev Saude Publica 47: 1080–1091.
-
29.
Velandia M , Castillo O , Higuera AB , Pastor D , 2004. Eliminación de la rubéola y el síndrome de rubéola congénita, plan de acción 2004–2010. Inf Quinc Epidemiol Nac 9: 321–336.
-
30.
Pinto DM , Muñoz AL , 2010. Colombia: Sistema general de seguridad social en salud. Estrategia del BID 2011–2014. Washington, DC: División de Protección Social y Salud, Inter-American Development Bank.
-
31.
De los Angeles Rodríguez M , Restrepo C , Uribe G , Díaz FJ , Jaramillo N , Melguizo M , 1999. Estado serológico para sarampión en población de uno a 14 años. Medellín 1996. Colomb Med (Cali) 30: 8–82.
-
32.
Bermúdez-Forero A , Mercado-Reyes M , Tavera P , Rey-Benito G , 2007. Determinación de la potencia del componente “sarampión” de la vacuna de virus vivo de sarampión y rubéola USP utilizada en la jornada de vacunacion 2005. Univ Sci (Bogota) 12: 87–94.
-
33.
Mercado MM , Rey G , Gutiérrez MF , Ruíz JG , Trespalacios AA , Bermudez A del P , 2009. Estimación de la proporción de seropositividad contra el sarampión en madres y presencia de anticuerpos antes y después de la vacuna en sus hijos de 6 y 12 meses de edad. Pediatria (Napoli) 42: 25–37.
-
34.
National Institute of Health, Republic of Colombia , 2019. PortalSivigila 2019 Buscador. Available at: http://portalsivigila.ins.gov.co/Paginas/Buscador.aspx#. Accessed November 25, 2020.
-
35.
Plotkin SA , 2020. Is there a correlate of protection for measles vaccine? J Infect Dis 221: 1571–1572.
-
36.
Bolotin S et al., 2020. What Is the evidence to support a correlate of protection for measles? A systematic review. J Infect Dis 221: 1576–1583.
-
37.
Ministerio de Salud y Protección Social, Republic of Colombia Información vacunas y programas de vacunación Ministerio de Salud Colombia. Available at: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/pai.aspx. Accessed July 10, 2021.
-
38.
Cetin Coban S et al., 2019. Prevalence of protective measles virus antibody levels in umbilical cord blood samples and sera of mothers and transplacental transport ratio in Turkey. Jpn J Infect Dis 72: 185–192.
-
39.
Gieles NC , Mutsaerts E , Kwatra G , Bont L , Cutland CL , Jones S , Moultrie A , Madhi SA , Nunes MC , 2020. Measles seroprevalence in pregnant women in Soweto, South Africa: a nested cohort study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 26: 515.e1–515.e4.
-
40.
Lam MTC , Schmidt-Beuchat E , Geduldig E , Brustman LE , Choi KH , Overbey JR , Woods KL , Al-Ibraheemi Z , 2021. What is the prevalence of measles immunity among pregnant women? Am J Perinatol 38: 16–22.
-
41.
Lee Y-C , Lee Y-H , Lu C-W , Cheng S-Y , Yang K-C , Huang K-C , 2020. Measles immunity gaps in an era of high vaccination coverage: a serology study from Taiwan. Travel Med Infect Dis 36: 101804.
-
42.
Gonçalves G , Frade J , Nunes C , Mesquita JR , Nascimento MSJ , 2015. Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal. Vaccine 33: 5057–5063.
-
43.
Poethko-Müller C , Mankertz A , 2012. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One 7: e42867.
-
44.
Vandermeulen C , Mathieu R , Geert L-R , Pierre VD , Karel H , 2007. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 25: 6672–6676.
-
45.
Arora M , Lakshmi R , 2021. Maternal vaccines—safety in pregnancy. Best Pract Res Clin Obstet Gynaecol 76: 23–40.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1856 | 1217 | 56 |
| Full Text Views | 233 | 35 | 0 |
| PDF Downloads | 120 | 30 | 0 |